BioNxt Solutions (TSE:BNXT)
:BNXT
Want to see TSE:BNXT full AI Analyst Report?
BNXT Stock Chart & Stats
C$0.64
-C$0.02(-3.85%)
At close: 4:00 PM EST
C$0.64
-C$0.02(-3.85%)
Day’s Range― - ―
52-Week RangeC$0.34 - C$1.10
Previous CloseN/A
Volume110.36K
Average Volume (3M)80.86K
Market Cap
C$52.38M
Enterprise ValueC$57.05M
Total Cash (Recent Filing)C$55.26K
Total Debt (Recent Filing)C$5.95M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding121,810,260
10 Day Avg. Volume59,081
30 Day Avg. Volume80,860
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)-8.07
Price to Sales (P/S)0.00
P/FCF Ratio-14.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform And Product FocusBioNxt’s core strategy targets reformulating existing active pharmaceutical ingredients into patient-friendly delivery formats. This platform approach can create repeatable licensing and commercialization opportunities, lowering discovery risk and supporting durable revenue avenues if partnerships are secured.
Lean Operating StructureA small headcount implies a lean cost base and operational flexibility, which helps extend runway under limited cash resources. For a cash-burning development-stage pharma company, lower fixed overhead is a durable advantage that preserves capital for R&D and business development.
Improving Cash Burn TrendManagement has reduced operating outflows versus peak burn years, which modestly lowers near-term refinancing pressure. A sustained downward cash-burn trend improves chances to bridge to partnerships or licensing deals, reducing financing frequency over the medium term.
Bears Say
Revenue CollapseAn abrupt fall to essentially zero revenue removes commercial validation and predictability for the business. Without recurring product sales or stable licensing income, the company’s ability to generate sustainable cash flows is materially impaired and increases dependency on external funding.
Persistent Operating LossesConsistent multi‑million dollar net losses erode capital and force repeated financing or dilution. Persistent negative profitability limits reinvestment capacity, weakens negotiating leverage with partners, and creates sustained pressure on solvency absent a material change in operations or funding.
Strained Balance SheetNegative equity and debt that far exceed a very small asset base sharply reduce financial flexibility. High refinancing and covenant risk can limit strategic options, raise funding costs, and increase the likelihood of dilution or restructuring over the medium term.
BioNxt Solutions News
BNXT FAQ
What was BioNxt Solutions’s price range in the past 12 months?
BioNxt Solutions lowest stock price was C$0.34 and its highest was C$1.10 in the past 12 months.
What is BioNxt Solutions’s market cap?
BioNxt Solutions’s market cap is C$52.38M.
When is BioNxt Solutions’s upcoming earnings report date?
BioNxt Solutions’s upcoming earnings report date is May 22, 2026 which is tomorrow.
How were BioNxt Solutions’s earnings last quarter?
Currently, no data Available
Is BioNxt Solutions overvalued?
According to Wall Street analysts BioNxt Solutions’s price is currently Overvalued.
Does BioNxt Solutions pay dividends?
BioNxt Solutions does not currently pay dividends.
What is BioNxt Solutions’s EPS estimate?
BioNxt Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioNxt Solutions have?
BioNxt Solutions has 121,810,260 shares outstanding.
What happened to BioNxt Solutions’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioNxt Solutions?
Currently, no hedge funds are holding shares in TSE:BNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNxt Solutions
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Avicanna
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---